Cell Line Development Market Size is valued at USD 1,042.7 Mn in 2023 and is predicted to reach USD 2,537.7 Mn by the year 2031 at a 12.1% CAGR during the forecast period for 2024-2031.
Cell line development creates highly productive, stable cell lines required for bio-therapeutic production and manufacture. These single-celled organisms create vaccines, monoclonal antibodies, and fusion proteins. Thousands of clones are screened during the development phase to locate those producing a significant volume of bi-product while also exhibiting essential quality traits. The features of cell lines make them more useful in synthesizing biological medicinal compounds. This raises the requirement for cell line development. As the biopharmaceutical sector grows, the cell line development (CLD) procedure is projected to be in high demand. The availability of improved methods for producing novel cell lines and an increase in demand for monoclonal antibodies and cancer medicines are expected to fuel market growth in the future years.
However, the supply chains for cell culture reagents, medium, equipment, and other vital components required in cell line creation have been hampered by worldwide lockdowns, travel restrictions, and interruptions in transportation and logistics. Many companies and research organizations have experienced delays, shortages, and cost increases as a result of these factors.
Competitive Landscape
Some Major Key Players In The Cell Line Development Market:
- Biovian
- Charles River Laboratories
- Creative Biogene
- KBI Biopharma
- Lonza
- ProBioGen
- Syngene International
- Thermo Fisher Scientific
- WuXi Biologics
- Advanced Instruments, LLC.
- AGC Biologics
- Catalent
- Corning Inc.
- Cyagen
- Cytiva
- Eurofins
- FUJIFILM Diosynth Biotechnologies
- GenScript Biotech Corporation
- Horizon Discovery
- Imgenex
- NAEJA RGM Pharmaceuticals
- Novartis
- Premas Biotech
- PromoCell
- Rentschler Biopharma SE
- Samsung Biologics
- Sartorius AG
- Selexis SA
- Vista Biologicals
- Other prominent players
Market Segmentation:
The Cell Line Development Market is segmented on the basis of source, application, and company size. As per the source, the market is segmented as Mammalian, Microbial, Insect, and Others. The application segment includes Research and Development and Drug Development. By company size, the market is segmented into Very Large and Large, Mid-sized, and Small.
Based On The Source, The Mammalian Segment Is A Major Contributor In The Cell Line Development Market.
The mammalian category is expected to hold a major share in the global Cell Line Development Market in 2022. The selection of cell line sources is necessary to develop economically viable, stable cell lines. Because of their higher complex protein expression capabilities, mammalian cell lines are most commonly used to manufacture monoclonal antibodies, vaccines, and biologics. Mammalian cell culture techniques are being explored to provide vaccines for diseases such as mumps, rubella, and measles in humans, as well as foot and mouth disease in veterinary medicine. It is the fastest-growing market due to the effective manufacture of biopharmaceuticals by mammalian cell lines, which can produce complex proteins in a manner similar to humans. This is predicted to enhance mammalian cell line source revenue share in the CLD market.
The Drug Development Segment Witnessed Growth At A Rapid Rate.
The drug development segment is estimated to grow rapidly in the global Cell Line Development Market. This is attributed to increased demand for pharmaceuticals and vaccine manufacture. Bio-production technology includes the development of biologics-based therapy medications such as vaccines, therapeutic proteins, cell treatments, and gene therapies. The most prevalent applications of bio-production are biologics and vaccines, and demand is expected to rise considerably in the future due to an increase in viral and infectious diseases, particularly in poor countries.
In The Region, The North America Cell Line Development Market Holds A Significant Revenue Share.
The North America Cell Line Development Market is expected to register the highest market share in revenue in the near future. This can be attributed to the benefits connected with cell culture techniques, such as cost-effectiveness and high productivity; cell culture techniques are becoming more popular. Factors contributing to market expansion include the presence of modern healthcare infrastructure, rising demand for biologics, and increased awareness of cell therapy, as well as relatively higher healthcare expenditure levels in the region. Asia Pacific is estimated to increase significantly in the future years. Key elements influencing this rapid expansion include the presence of unexplored prospects, economic development, improved healthcare infrastructure, and favourable measures by the government and manufacturers in the biotechnology sector.
Recent Developments:
- In Dec 2023, FUJIFILM Corporation declared its intention to invest USD 200 million in two subsidiaries with the aim of substantially enhancing its global capabilities in contract development and manufacturing (CDMO) for cell therapy. The investment facilitated Fujifilm's backing of the burgeoning cell therapy sector, projected to experience an annual growth rate of 30%.
- In July 2022, Granite Bio and ProBioGen teamed up to offer GMP manufacturing and cell line creation services. A novel monoclonal antibody is Granite Bio's primary candidate for treating autoimmune and cancer diseases. DirectedLuck is a transposase.
Cell Line Development Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 1,042.7 Mn |
|
Revenue Forecast In 2031 |
USD 2,537.7 Mn |
|
Growth Rate CAGR |
CAGR of 12.1 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Application, Source of Cell Lines, Company Size |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Biovian, Charles River Laboratories, Creative Biogene, KBI Biopharma, Lonza, ProBioGen, Syngene International, Thermo Fisher Scientific, WuXi Biologics, Advanced Instruments, LLC., AGC Biologics, Catalent, Corning Inc., Cyagen, Cytiva, Eurofins, FUJIFILM Diosynth Biotechnologies, GenScript Biotech Corporation, Horizon Discovery, Imgenex, NAEJA RGM Pharmaceuticals, Novartis, Premas Biotech, PromoCell, Rentschler Biopharma SE, Samsung Biologics, Sartorius AG, Selexis SA, Vista Biologicals, Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
